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We introduced rat ornithine tr=msuarbamylar~ (OT¢I ge~ne into OTC.defi¢i~nl ~pf.ash mice by mntinil ~pr.a=h Itet=ro~gole~ with irnn~geni¢ mice 
which carried rec0mbin~mt DNA composed of 1,3 kh of the ~' Ilankinlil region of the gene fused onto rat OTC eDNA. The llver OT(.' =tetivity 
of hemiayllous =pf.ash mice which carried the !r|~.l~|llefle ~as about twice that o1" nontransllenic =pf-a=~h mice, and the ~n~all inteltlna) OTC activity 
was 6 times hillh©r; the Values being 12~ and 2"/~ ofthecontrol evels, r¢=p~:tively, The Iransllenic ~pl'.ash mice sltowed normal hair growth ,without 
spars = fur, nca~'iy normalixed urinary erotic a~id excretion and normalized ~rum citrulllne conw~ttalion. 
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1. INTRODUCTION 
Ornithine transcarbamylase (OTC)is a mitochon- 
drial urea cycle enzyme located only in the liver and 
small intestine. Hepatic OTC Plays an important role in 
ammonia detoxication and bicarbonate excretion [1] as 
a member of the urea cycle, whereas OTC in the small 
intestine is thought o supply eitrulline mainly to the 
kidney for the synthesis of arginine [2]. It is not known 
whether small intestinal OTC plays any role in am- 
monia detoxication. Two types of OTC,deficient mice 
have been found, sparse.fur (spf) [3] and sparse-fur 
with abnormal skin and hair (spf.ash) [4], which had 
decreased OTC activity both in the liver and small in- 
testine [5]. Their molecular and genetic defects have 
been analyzed [6-8]. As their names imply, they have 
• delayed hair growth and, as in human OTC deficiency, 
they show hyperammonemia, erotic aciduria and low 
concentrations of serum citrulline and arginine 
[3,4,9,10]. Cavard et al. [11] produced a transgenic spf- 
ash mouse by introducing into the fertilized eggs of spf- 
ash mice a construct containing rat OTC eDNA linked 
to SV40 early promoter. They reported that the OTC 
activity in the liver and small intestine reached 80=90~0 
of control values and that the phenotype and erotic acid 
excretion of the transgenic mouse was fully normalized. 
Murakami et al. [12] introduced reconibinant DNA car- 
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rying 1,3 kb of the 5' flanking region of the rat OTC 
gene fused to the rat OTC eDNA into fertilized mouse 
eggs and established transgenic mice wh ch expressed 
rat OTC tissue-specifically. Hepatic expression, how- 
ever, was low, probably because of the lack of the en. 
hancer element [I 3]. This transgenic mouse in combina- 
tion with OTC-defictent mice may be useful for study- 
ing the role of small intestinal OTC. We introduced rat 
OTC eDNA with its own promote r into spf-ash mice by 
mating spf-ash heterozygotes with the OTC-transgenic 
micel Here we describe the increase in liver and srnall in, 
testine OTC activities and the correction of the pheno- 
types of spf-ash mice. During the preparation of this 
manuscript, a paper by Jones et al. [14] has appeared 
that describes the correction of OTC deficiency in spf 
mice by introducing human OTC eDNA carrying 
mouse OTC promoter. 
2.  MATERIALS AND METHODS 
2.1 Animals  
Heterozysous spf-ash mice (X'/X), C57BL strain, were mated with 
transsenic mice (+/ - )  of the sarne (C57BL)strain, F4 of no. 94 
described in [12]. We confirmed the presence of rat OTC gene in the 
genome by Southern blot analysis of the DNA extracted from the tail 
as described in [12] and confirmed the spf-ash gene by~ measuring 
OTC activity in the small intestine and liver. The mice were separated 
from their mothers at 21 days and maintained on a laboratory CE2 
chow from Clea Japan Inc, Urine samples were collected in metabolic 
cage at 27 to 29 days of al~e. Serum samples were separated from 
blood specimens obtained by heart puncture, 
2.2. Assay methods 
For the assay of OTC activity, liver homogenate and extract of 
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~mall tntesllae w~r¢ prvl~fed ~ d~es¢rfl~d by G~ashiken el ~1, 19) ~nd 
~4amkiuml el at. l l l l .  ^<t|vll~ .~t  a~,~p~d by the me;ho, d ¢=1' Piwsan 
el ~1, [l$l. Urinary ~o11¢ ~<hl ~nd er~lillirl~ were mc~l~gr~d ~¢, 
~ordlntn to Ihe m~thod~ hi' Kesn¢1' wl .l. [ 16) ~nd I]¢mn~ and Tuu~ky 
I | l l .  ser,m amino ~kh were quantlrkd by rewrse.phate liquid 
ehromatoilr~phy after d~elvali,~alloll wl~lt =,phlhalaldeh)'d¢ at. 
¢ordinll |o Ih¢ m,~lhod or God¢l ¢; at. [lltt. 
3. RESULTS AND DISCUSSION 
We obtained four types of experimental male mice 
(X/Y, - / - )  or control ( - ) ,  (X'/Y, -~- )or  ash 
( - ) ,  (X/Y, +/- )  or control (÷), and (X' lY, + / - )  
or ash(+ ). OTC activity in the liver of the ash(+ ) mice 
was 1.9 times higher than that of ash(- ), the value be. 
ing 12% or" that or tire control alice (Table D. On tile 
other hand, OTC activity in the small intestine of 
spf(+ ) mice was 6,3 times higher than that of ashC- ), 
reaching 2"/°70 of' the control value. The low value in the 
liver is apparently due to the lack of OTC enhancer 
elements [12,13] in the present construct. No significant 
difference was observed between OTC activity in the 
liver and small intestine of  control( + ) and control(- )
mice. In spite of lower than nornml OTC activity in the 
liver and small intestine of ash(+) mice, these mice 
showed no sparse-fur phenotypo. Introduction of the 
rat OTC gone into spf-ash mice approximately doubled 
the serum citrulline concentration toa level comparable 
to the control value. These results uggest that small in- 
testinal OTC activity (27% of the control) ts enough to 
maintain serum citrulline at normal levels, There was 
no significant difference in the concentration of argini- 
ne among the different ypes of mice, probably because 
they were well fed. There was no increase in blood am- 
monia even in ash( - )  mice under the present conditions 
(data not shown). 
The introduction of rat OTC gone into spf-ash mice 
resulted in a dramatic decrease m urinary erotic acid 
concentration (Table !), The level in ash(+ ) mice was 
almost normal. Althoush a hillh concentration or erotic 
acid in the urine is a good indicator or OTC deficiency 
and is thoL=ght to be caused by deficiency or liver OTC, 
it isnot known whether or to what extent deficiency of 
small intestinal OTC contributes to erotic aciduria. 
Recently ]ones et al. [14] reported similar results with 
transgenic spr mice which carried human OTC gene 
witli truncated mouse promoter; tile mice showed no 
OTC deficiency phenotype, expressed a large amount 
of human OTC in the small intestine, but almost none 
inthe liver. The difference in liver and small intestinal 
OTC expression betwee== Jones et al, and the present 
study may be due to the OTC promoter used, mouse 
and rat, or to the insertion site of the transgenes, Their 
results described below are not easy to understand, 
Their spf mice had small intestinal OTC activity higher 
than control, and their transgenic spf mice had urinary 
erotic acid excretion reduced to the normal level in spite 
of the fact that there was no change in OTC activity in 
the liver where most of ammonia is formed and car, 
bamylphosphate would accumulate. From our results, 
we cannot conclude whether the decrease in erotic acid 
excretion is due to increased OTC activity in the small 
intestine or in the liver of OTC.deficient mice. 
In any case, it is noteworthy that the ash(+) mice, 
having OTC activity about one-tenth and one-fourth of 
the controls in the liver and small intestine, respectively, 
showed almost no laboratory findings characteristic to 
OTC deficiency. Severe hyperammonemia was reported 
in human patients, with hepatic OTC activity at 
30-50°70 of the controls [19]. This is probably due to 
species difference, or nlay support he observation that 
symptomatic manifestations break out in late.onset 
OTC deficiency follovcing ingestion of a high protein 
diet or accelerated protein breakdown caused by injury 
or infection. It remains to be seen to what extent he 
ash(+) mice are resistant o nitrogen load. 
Table 1 
OTC activities in the liver and small intestine, concentrations of serum citrulline and arginine and  urinary erotic 
acid excretion of  control and spf.ash mice, and those carrying rat OTC gone 
Mice OTC activity (U/mR protein) Serum amino acid Urinary erotic 
(nmollml) acid 
Arg (nmol /mg cr) Liver Small intestine Cit 
Cont ro l ( - )  1,09 _ 0.42 0,258 -,- 0,065 76 z 16 196 :: 50 477 ± 303 
(n) (6) (6) (4) (4) (6) 
Contro l (w)  0,928 a: 0,256 0,229 -,- 0,079 67 -,- 6 176 -,- 48 634 ± 255 
(n) (9) (9) (4) (4) (6) 
Ash( - )  0,067 =: 0,014 b 0,011 -,- 0,004 b 36 z 16 a 165 -,- 50 7850 ± 4280 b 
(n) (6) (6) (4) (4) (6) 
Ash(+)  0,126 ~ 0,027 b'¢ 0,069 :e 0,019 t''d 63 -,- 11 ~ 188 -,- 21 907 ::1:141 m'c 
(n) (4) (4) (4} (4) (4) 
Values significantly different f rom those of  cont ro l ( - )  - "P<0,05  and bP<0.01;  and values of ash(+)  
significantly different from those o f  ash( -  ) - ¢P<:0,05 and"P< 0,01, 'Control '  and 'ash' denote control and spf- 
ash mice; ( - ) and (+) ,  absence and presence of rat OTC gone, cr, creatinine; (n). number o f  animals examined. 
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